BioSpace News Archive

Affimed will not seek accelerated approval for AFM13 as a monotherapy in advanced-stage relapsed/refractory peripheral T cell lymphoma.

Teaming up with a recruiter can be a smart move in a tight job market or for job seekers looking for a specialized role. To help you in your job search, we’ve outlined how to get the best out of recruiters.

Seagen’s top-selling drug hit the mark in another major indication.

Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.

Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.

Clovis Oncology officially files for Chapter 11 bankruptcy.

Poolbeg Pharma announces that, further to its announcement in July 2022, it has now received the initial results having completed the Lipopolysaccharide human challenge clinical trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need for severe influenza.

Inventiva announced the receipt of the €25 million payment under the first tranche of the unsecured loan agreement executed with the European Investment Bank on May 16, 2022 with a maturity date of December 2026.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to announce the successful completion of its first Process Qualification run of the end-to-end process for the manufacture of HEMO-CAR-T cells.

Akeso Inc. announced that the Journal for Immunotherapy of Cancer, a BMJ oncology journal, published the mechanism of action of its Ligufalimab.